Clinical Trials Directory

Trials / Completed

CompletedNCT03398681

Changes in Myocardial Iron After Iron Administration

Changes in Myocardial Iron Content Following Administration of Intravenous Iron (Myocardial-IRON)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
53 (actual)
Sponsor
Fundación para la Investigación del Hospital Clínico de Valencia · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Recent studies have shown that treatment with intravenous iron in patients with iron deficiency (ID) and heart failure with reduced ejection fraction (HFrEF) improves symptomatology, functional capacity, quality of life, and decreases hospitalizations regardless of anemia. In addition, a decrease in myocardial iron content has been observed in patients with chronic HFrEF. This preliminary evidence has led to postulate that myocardial iron deficiency could play a direct role in the pathogenesis and progression of the disease. The investigators hypothesize that the repletion of myocardial iron would explain part of the benefit of this treatment. Thus, the investigators postulate that cardiac magnetic resonance (CMR) (T2\* and T1-mapping sequences) will be sensible enough to detect changes in myocardial iron content as a result of intravenous iron administration, and that such changes will correlate with simultaneous changes in parameters of heart failure severity. In this double-blind 1:1 randomized study controlled by placebo the investigators aim to determine the changes in myocardial iron content after treatment with intravenous ferric carboxymaltose (FCM) by CMR at 7 and 30 days in patients with stable HFrEF and ID.

Conditions

Interventions

TypeNameDescription
DRUGFerric carboymaltoseFerric Carboxymaltose solution \[Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)\]
DRUGPlacebo (Normal saline)Normal saline (0.9% weight/volume (w/v) NaCl)
DIAGNOSTIC_TESTCardiac magnetic resonanceCardiac magnetic resonance including T2\* and T1-mapping sequences

Timeline

Start date
2017-05-01
Primary completion
2018-07-30
Completion
2018-07-30
First posted
2018-01-12
Last updated
2019-07-30

Locations

6 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT03398681. Inclusion in this directory is not an endorsement.